Abstract
Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Current Topics in Medicinal Chemistry
Title: Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Volume: 11 Issue: 21
Author(s): Chee Fei Chin, Daniel Yuan Qiang Wong, Ramasamy Jothibasu and Wee Han Ang
Affiliation:
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Abstract: Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Export Options
About this article
Cite this article as:
Fei Chin Chee, Yuan Qiang Wong Daniel, Jothibasu Ramasamy and Han Ang Wee, Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity, Current Topics in Medicinal Chemistry 2011; 11 (21) . https://dx.doi.org/10.2174/156802611798040778
DOI https://dx.doi.org/10.2174/156802611798040778 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Cystitis Caused by Commensal Neisseria oralis: A Case Report and Review of the Literature
Infectious Disorders - Drug Targets Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction
Current HIV Research The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Oral Cavity-Associated Immune System: What is New?
Current Immunology Reviews (Discontinued) Urine-derived Stem Cells, A New Source of Seed Cells for Tissue Engineering
Current Stem Cell Research & Therapy <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review
Current Reviews in Clinical and Experimental Pharmacology New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
Current Clinical Pharmacology MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Genetics of Congenital Heart Disease
Current Cardiology Reviews Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Current Medicinal Chemistry - Anti-Cancer Agents The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Anti-Cancer Agents in Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design